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1. INTRODUCTION
This report is submitted, as required by Chapter 75, Section 43(f), on the activities of the
MassBiologics of the University of Massachusetts Medical School. This is the nineteenth
year of such annual report.
The following sections provide the required information as follows:
Part 2, Prior Fiscal Year (FYl 5) Information, as indicated by legislation, describes the patents
and licenses, agreements entered into, status of existing agreements, royalties and other
benefits, and expenditures, current assets and liabilities. This section includes two schedules:
(1) FY15 Balance Sheet and (2) FY15 Statement of Revenues and Expenditures and Other
Charges. Included here is information related to appropriated funds for the prior fiscal year,
as required by the legislation.
Part 3, Financial Plans, presents projected revenues and expenses. A three-year projection is 
included. 3 
2 PRIOR FISCAL YEAR (FY15) INFORMATION 
This section of the report presents the specific information indicated in the legislation 
related to the prior fiscal year (FY15: July 1, 2014 - June 30, 2015). This is the nineteenth 
full year in which MassBiologics has operated within the University of Massachusetts. 
The effective date of the transfer to the University of Massachusetts was January 1, 1997. 
a. Patents and Licensing
MassBiologics has had eight patents with claims allowed in FYI 5:
Antibodies Against Clostridium Difficile Toxins and Uses Thereof 
1) 2/31/2014 European Patent No. 2270045
2) 3/27/2015 Japanese Patent No. 5717300
Human Antibodies Against Rabies and Uses Thereof 
1) 4/30/2014 South African Patent No. 2007/07339(notified March 13, 2015)
2) 7/25/2014 Hong Kong Patent No. HKl 104060
Human Antibodies Against Hepatitis C Virus (HCV) and Uses Thereof 
1) 7/25/2014 Hong Kong Patent No. HKl 138297
2) 11/7/2014 Japanese Patent No. 5642972
3) 4/14/2015 Canadian Patent No. 2,768,888
4) 4/29/2015 Korean Patent No. 1518081
b. Agreements entered into
MassBiologics entered into a new exclusive distribution agreement with Grifols
Worldwide Operations Ltd. for the distribution of Tetanus and Diphtheria vaccine for a
one year term ending June 30, 2016.
MassBiologics entered into a series of research and collaboration agreements as follows:
1) Voyager Therapeutics Inc. - Strategic Collaboration Agreement for adeno
associated virus (AA V) products, effective 10/20/2014
2) Life Technologies Corporation - Cell Line Services License agreement effective
12/19.2014
3) Life Technologies Corporation - Commercial Production License effective
5/1/2015
4) AbCellera Biologics Inc. - materials transfer and collaborative research (ETEC)
effective 10/6/2014
5) Adimab, LLC - materials transfer and collaborative research (Ebola) effective
2/9/2015
6) Scripps Research Institute - materials transfer and collaborative research (Ebola)
effective 2/13/2015
7) Tufts University - research collaboration (Lyme) effective 5/1/2015
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MassBiologics signed Master Service Agreements with 2 new biopharmaceutical 
companies ( client names withheld per non-disclosure agreements), executed 41 work order 
agreements that will generate $10,342,106 in new revenue, while continuing to build a 
pipeline of new potential customers for its contract manufacturing services. 
MassBiologics opened its new South Coast Vector Manufacturing Center and signed a 
long term development contract for the production of cutting edge gene therapy products 
with its first client. 
c. Grants and Contracts Awarded
DARPA-Award of $4,379,245 was received from Defense ADV Research 
Projects Agency effective July 1, 2013 through May 30, 2017. $2,210,905 of 
funding was received in FYl 5. 
R24 Grant - Award of$1,332,331 was received from National Institutes of 
Health effective May 29, 2013 through April 30, 2015 and this grant received a 
no cost extension through January 31, 2016. $618,149 of funding was received 
in FY15. 
NIH Contract - Award of $3,568,089 was received from NIH-Nat'l Inst. of 
Allergy & Infectious Disease effective September 29, 2013 through September 
28, 2015. $1,679,523 of funding was received in FY15. 
NIH Grant -Award of $762,436 was received from NIH-Nat'l Inst. of Allergy & 
Infectious Disease effective May 1, 2014 through April 30, 2017. $443,072 of 
funding was received in FY15. 
MLSC Grant - Award of $5,000,000 was received from Massachusetts Life 
Sciences Center effective July 1, 2014 through June 30, 2016. $3,189,961 of 
funding was received in FY15. 
EOHED Grant-Award of$5,000,000 was received from MassWorks 
Infrastructure Program effective December 10, 2014 through June 30, 2016. 
$954,742 of funding was received in FY15. 
d. Status of existing agreements, royalties and other benefits
MassBiologics had the following major existing agreements in FY15.
Bristol-Meyers Squibb, formerly Medarex - a collaborative development agreement had
previously been signed April 17, 2002 with a public company (Medarex). This agreement
remains in place in support of MassBiologics' continued research.
The Materials Cooperative Research and Development Agreement (M-CRADA) that was
entered into January 30, 2004 with the CDC for Rabies was extended until January 30,
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2006. Subsequently, that agreement evolved into an Inter-institutional Agreement that was 
executed in August, 2005. 
Merck Exclusive License Agreement April 20, 2009 for antibodies against C. Difficile. 
This agreement remains in place in support of continued clinical development of 
MassBiologics' proprietary CDiff antibodies. 
Serum Institute oflndia License and Collaboration Agreement effective September 27, 
2006. This agreement remains in effect for the development and commercialization of a 
rabies monoclonal antibody for the treatment of rabies. 
Grifols Inc. - Research Collaboration and License effective 5/17/2014 for the development 
of a rabies monoclonal antibody therapeutic in North America. 
Grifols Inc - Distribution Agreement for Td vaccine in USA and Canada, effective 
7/1/2015 
Sale of Reagents: Reagents are by-products of the major manufacturing products of 
MassBiologics. MassBiologics makes these reagents available for research purposes. 
e. Revenues, expenditures, assets and liabilities
On the pages that follow, please find two schedules: (1) FYI 5 Statement of Revenues and
Expenditures and Other Charges, and (2) FY15 Balance Sheet. This information is
reviewed as part of the University of Massachusetts annual audit and is included as part of
comprehensive financial reports made to the University of Massachusetts' Board of
Trustees. Financial activities are also reported to the Office of the State Comptroller.
When reviewing these schedules, please note:
• State Appropriations / DPH represents the DPH appropriated fund support of the
effort at the Biologic Laboratories of $802,685. These funds only partially support
staff and provide the supplies and equipment used in the production oLvaccine
which i's distributed to residents of Massachusetts without charge. The vaccine
that is provided is Tetanus-Diphtheria vaccine (Td).
• License and Royalty Fees represents such payments received for CMV-IGIV, and
monoclonal antibodies to RSV and C. difficile.
The Plant Fund is to cover the replacement of major equipment, essential facility 
improvements necessary to meet FDA and other manufacturing license requirements. This 
account includes the cumulative capitalized equipment purchases and building 
improvements and a balance of unexpended funds in reserve for planned equipment 
purchases and building improvements. In FY15, the plant fund continued to also be used to 
conclude the new facility expenses. 6 
The core activities ofMassBiologics remained consistent though FY15. In calendar year 
2008 the MassBiologics received its licensure from the FDA to bring its new production 
facility on line. MassBiologics continued to manufacture clinical material in the new 
facility to support its IND activities. 
The new production facility is located at the old Boston State Hospital location. This 
location was authorized by the legislature in July 2000 and opened October 2005. To 
support the costs of the new facility, Worcester City Campus Corporation borrowed in 
FY02 in reliance on its lease with the University of Massachusetts Medical School acting 
on behalf ofMassBiologics. The plant fund represents payment of the lease payments 
supporting the bonds, as well as other capital costs associated with Worcester City Campus 
Corporation, the University of Massachusetts Medical School and the capital needs and 
operations of MassBiologics. 
Construction of Mattapan II was completed in the late spring of 2010. The project was on 
time and within budget. Mattapan II was also occupied in this timeframe. 
To support the costs ofMattapan II, Worcester City Campus Corporation borrowed $35 
million in FY 07 in reliance on its lease with the University of Massachusetts Medical 
School acting on behalf of the MassBiologics. 
It was determined that MassBiologics would benefit from consolidating its operations to 
one campus by making facilities modifications to the Mattapan Campus. Modifications 
completed by June 2013 made it possible for MassBiologics to leave the Jamaica Plain 
Campus effective June 30, ending a 119 year tenancy at that campus. Commissioning and 
validation activities are ongoing and it is expected that Td vaccine manufactured in the 
newly created space will be available for release and human use by the end of fiscal 2015. 
In fiscal 2015 it was determined that the MAB facility developed under the guidance of the 
UMass Dartmouth campus would be a better strategic fit if it were configured as a cGMP 
manufacturing resource for the development of vectored therapeutics under the operational 
control ofMassBiologics. To that end the previously identified grants totaling $10M from 
the MLSC and Mass Works are being invested in the facility located at 1240 Innovation 
Way to support the cGMP requirements of vector manucturing. 
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University of Massachusetts Biologic Laboratories 
Statement of Revenues, Expenditures and Other Changes 
For the Period July 1, 2014 Through June 30, 2015 
(Unaudited) 
CURRENT APPROPRIATED 
REVENUE AND OTHER ADDITIONS: 
Product Sales 
Restricted Grants & Contracts 
State Appropriations/DPH 
Royalty Fees and Interest 
Recovery of Indirect Costs 
Other Income 
Total Revenue and Other Additions 
EXPENDITURES AND OTHER DEDUCTIONS: 
Salaries 
Fringe Benefits 
Supplies and Services 
Depreciation 
Total Expenditures and Other Deductions 
Net lncrease/(Decrease) Before Transfers 
Nonmandatory Transfers 
Transfers 
Total Transfers 'l:"' 
Other Changes 
Excess of Restricted Receipts over Transfers to Revenue 
NET INCREASE(DECREASE) FOR THE YEAR 
Fund Balances at Beginning of Year (7/1/14) 
FUND BALANCES AT END OF YEAR 
FUND FUNDS 
16,751,153 
8,512,520 
769,748 
23,920,921 
526,667 
1,091,306 
50,802,567 769,748 
16,971,716 412,339 
5,004,296 112,007 
26,493,766 245,402 
1,739,911 
50,224,503 769,748 
578,064 0 
20,600,000 0 
20,600,000 0 
0 0 
21,178,064 0 
42,719,943 0 
63,898,007 0 
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TOTAL 
16,751,153 
8,512,520 
769,748 
23,920,921 
526,667 
1,091,306 
51,572,315 
17,384,055 
5,116,303 
26,739,168 
1,739,911 
50,994,251 
578,064 
20,600,000 
20,600,000 
0 
21,178,064 
42,719,943 
63,898,007 
Assets 
Cash 
Accounts Receivable 
Inventory 
Prepaid Expenses 
Buildings & Equipment 
Other Assets 
Total Assets 
Liabilities 
Accounts Payable 
University of Massachusetts Biologic Laboratories 
Balance Sheet 
As of June 30, 2015 
(Unaudited) 
CURRENT FUND PLANT FUND 
FY15 FY15 
11,744,700 1,112,929 
19,834,638 
8,203,313 
182,905 244,705 
26,627,633 
39,965,556 27,985,264 
3,078,134 158,154 
Employee-Related Accruals 816,528 
Other Liabilities 
Total Liabilities 
Fund Balances 
Total Liabilities and Fund 
Balance 
3,894,662 158,154 
36_,070_,894 27,827,113 
39,965,556 27,985,267 
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TOTAL FY15 
12,857,629 
19,834,638 
8,203,313 
427,610 
26,627,633 
67,950,823 
3,236,288 
816,528 
4,052,816 
63,898,007 
67,950,823 
Financial Plans 
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University of Massachusetts Biologic Laboratories 
Statement of Revenues, Expenditures and Other Changes 
For the Period July 1, 2015 Through June 30, 2016 
REVENUE AND OTHER ADDITIONS: 
Product Sales 
Restricted Grants & Contracts 
State Appropriations/DPH 
Royalty Fees and Interest 
Recovery of Indirect Costs 
Other Income 
Total Revenue and Other Additions 
EXPENDITURES AND OTHER DEDUCTIONS: 
Salaries 
Fringe Benefits 
Supplies and Services 
Depreciation 
Total Expenditures and Other Deductions 
Net lncrease/(Decrease) Before Transfers 
Nonmandatory Transfers 
Transfers 
Total Transfers 
Other Changes 
(Unaudited) 
Excess of Restricted Receipts over Transfers to Revenue 
NET INCREASE(DECREASE) FOR THE YEAR 
Fund Balances at Beginning of Year (7/1/15) 
FUND BALANCES AT END OF YEAR 
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CURRENT 
FUND 
27,067,555 
5,823,105 
46,143,792 
583,636 
318,220 
79,936,308 
20,388,666 
6,315,487 
38,590,283 
2,216,955 
67,511,391 
12,424,917 
4,355,000 
4,355,000 
16,779,917 
63,898,007 
80,677,924 
APPROPRIATED 
FUNDS 
802,685 
802,685 
--
412,339 
112,007 
278,339 
802,685 
0 
0 
0 
0 
0 
0 
TOTAL 
27,067,555 
5,823,105 
802,685 
46,143,792 
583,636 
318,220 
80,738,993 
20,801,005 
6,427,494 
38,868,622 
2,216,955 
68,314,_Q76 
12,424,917 
4,355,000 
4,355,000 
16,779,917 
63,898�0Q7 
§0,677,924
University of Massachusetts Biologic Laboratories 
Statement of Revenues, Expenditures and Other Changes 
For the Period July 1, 2016 Through June 30, 2017 
(Unaudited) 
CURRENT APPROPRIATED 
REVENUE AND OTHER ADDITIONS: 
Product Sales 
Restricted Grants & Contracts 
State Appropriations/DPH 
Royalty Fees and Interest 
Recovery of Indirect Costs 
Other Income 
Total Revenue and Other Additions 
EXPENDITURES AND OTHER DEDUCTIONS: 
Salaries 
Fringe Benefits 
Supplies and Services 
Depreciation 
Total Expenditures and Other Deductions 
Net lncrease/(Decrease) Before Transfers 
Nonmandatory Transfers 
Transfers 
Total Transfers 
Other Changes 
Excess of Restricted Receipts over Transfers to Revenue 
NET INCREASE(DECREASE) FOR THE YEAR 
Fund Balances at Beginning of Year (7/1/16) 
FUND BALANCES AT END OF YEAR 
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FUND FUNDS 
24,544,815 
4,128,105 
802,685 
46,970,447 
583,636 
396,800 
76,623,803 802,685 
21,738,037 412,339 
6,732,426 112,007 
39,852,214 278,339 
2,729,243 
71,051,920 802,685 
5,571,883 0 
0 0 
0 0 
5,571,883 0 
80,677,924 0 
86,249,807 0 
TOTAL 
24,544,815 
4,128,105 
802,685 
46,970,447 
583,636 
396,800 
77,426,488 
22,150,376 
6,844,433 
40,130,553 
2,729,243 
71,854,605 
5,571,883 
0 
0 
5,571,883 
80,677,924 
8624_9,1307 
, 
University of Massachusetts Biologic Laboratories 
Statement of Revenues, Expenditures and Other Changes 
For the Period July 1, 2017 Through June 30, 2018 
REVENUE AND OTHER ADDITIONS: 
Product Sales 
Restricted Grants & Contracts 
State Appropriations/DPH 
Royalty Fees and Interest 
Recovery of Indirect Costs 
Other Income 
Total Revenue and Other Additions 
EXPENDITURES AND OTHER DEDUCTIONS: 
Salaries 
Fringe Benefits 
Supplies and Services 
Depreciation 
Total Expenditures and Other Deductions 
Net lncrease/(Decrease) Before Transfers 
Nonmandatory Transfers 
Transfers 
Total Transfers 
Other Changes 
(Unaudited) 
Excess of Restricted Receipts over Transfers to Revenue 
NET INCREASE(DECREASE) FOR THE YEAR 
Fund Balances at Beginning of Year (7/1/17) 
FUND BALANCES AT END OF YEAR 
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CURRENT 
FUND 
26,127,711 
4,128,105 
46,102,280 
583,636 
550,471 
77,492,203 
21,955,429 
6,799,618 
45,251,694 
3,006,128 
77,012,869 
479,334 
0 
0 
479,334 
86,249,807 
86,729,141 
APPROPRIATED 
FUNDS 
802,685 
802,685 
412,339 
112,007 
278,339 
1302_,68§ 
0 
0 
0 
0 
0 
0 
TOTAL 
26,127,711 
4,128,105 
802,685 
46,102,280 
583,636 
550,471 
78,294,888 
22,367,768 
6,911,625 
45,530,033 
3,006,128 
77,815,554 
479,334 
0 
0 
479,334 
86,249,807 
86,729,141 
